Delivery Order 75N93019D00011-75N93024F00002
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $159,000 delivery order to Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, for in vitro testing to determine the inhibitory effects of experimental antibacterial substances against bacterial pathogens. The contract, which was awarded on August 4, 2023, with an ultimate completion date of August 3, 2024, operates under a firm fixed-price structure with no small business set-aside...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $570K delivery order to Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, for determination of the in vitro inhibitory effect of experimental antibacterial substances against bacterial pathogens. The firm fixed-price contract was awarded on May 23, 2024, with an ultimate completion date of May 22, 2025, and will be performed in North Liberty, Iowa. This award falls under the In Vitro...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $755.7K delivery order to Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, on September 16, 2021, with completion targeted for September 15, 2022. Under this firm fixed-price contract, JMI Laboratories will determine the in vitro inhibitory effect of experimental antibacterial substances against bacterial pathogens using minimum inhibitory concentration (MIC) testing methodologies. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $195.7K delivery order to Element Materials Technology Iowa City Inc., operating as JMI Laboratories, for in vitro screening of antibacterial activity against public health disease pathogens. The contract, which was awarded on April 21, 2022, with an ultimate completion date of May 1, 2023, is structured as a firm fixed-price delivery order under the In Vitro Assessments of Antimicrobial Activity (IVAAA)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $981.3k to Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, on June 21, 2019. This task order, designated A02, falls under the In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite-delivery/indefinite-quantity contract vehicle and supports screening of natural product libraries for antimicrobial activity. The contract utilizes cost-plus-fixed-fee...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $236,000 firm fixed-price delivery order to Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, for antibacterial minimum inhibitory concentration (MIC) testing of a gram-negative targeted compound collection. The contract, which was awarded on June 12, 2023, with an ultimate completion date of June 11, 2024, will be performed in North Liberty, Iowa. This delivery order was issued under the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14,311 firm fixed-price delivery order to Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, on July 22, 2019. This task order, designated Task A06, requires JMI Laboratories to determine the in vitro minimum inhibitory concentration (MIC) of a candidate antimicrobial product against a panel of Listeria monocytogenes clinical isolates. The work will be performed in North Liberty, Iowa, with...
- Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, was awarded a $76,000 delivery order on January 11, 2019, under the In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite-delivery/indefinite-quantity contract vehicle. The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, funded this civilian contract to conduct in vitro assessments of antimicrobial activity against bacterial species....
- The National Institute of Allergy and Infectious Diseases issued a $32,500 delivery order to Element Materials Technology Iowa City Inc. (doing business as JMI Laboratories) on January 14, 2025, under the In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite-delivery/indefinite-quantity contract for bacterial in vitro screening services. The order carries a ceiling value of $65,000. Place of performance is North Liberty, IA 52317. The ultimate completion date is January 13, 2027....
- Element Materials Technology Iowa City Inc., operating as JMI Laboratories, was awarded a delivery order valued at $193,325 by the National Institute of Allergy and Infectious Diseases (NIAID) on August 31, 2023. The contract, which will be completed by August 30, 2024, requires the contractor to determine the in vitro minimal inhibitory concentration (MIC) of candidate products against a panel of Neisseria gonorrhoeae isolates. This delivery order was issued under the In Vitro Assessments of...
- 75N93019D00011Indefinite Delivery Contract
- 75N93019D00011-75N93024F00002Delivery Order
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $112.4K delivery order contract to Element Materials Technology Iowa City Inc., doing business as JMI Laboratories, on August 14, 2024, with completion expected by August 13, 2025. This firm fixed-price contract supports in vitro screening for antibacterial activity against public health disease pathogens and determination of the in vitro inhibitory effect of experimental antibacterial substances against bacterial pathogens. The contract was issued without a small business set-aside designation and is issued under the In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite-delivery/indefinite-quantity contract vehicle administered by NIAID. Work will be performed in North Liberty, Iowa. JMI Laboratories is a microbiology specialist that has been registered to receive federal contracts since November 2016 and maintains extensive experience conducting antimicrobial resistance testing and research services for the Department of Health and Human Services. The company specializes in in vitro assessments of antimicrobial activity, minimum inhibitory concentration assays, and analysis of antimicrobial resistance pharmacogenetic relationships to support critical public health challenges related to emerging resistance trends. The firm has previously received multiple awards under the IVAAA contract vehicle and maintains a track record of delivering specialized antimicrobial research support to federal agencies including the Food and Drug Administration and National Institutes of Health.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Funding Only Action | ($25k) | 8/29/25 | |
| Not listed | Not listed | $70.0k | 8/13/24 |